Figure 1.
Elevated MYC expression in human triple-negative cancers. (A) MYC mRNA expression in triple-negative versus receptor-positive primary breast tumors collected through the I-SPY TRIAL (P < 0.0001). (B) MYC and phospho-MYC (T58/S62) protein expression in triple-negative primary tumors. Shown is an independent cohort of 208 patients for which quantitative reverse-phase protein arrays were performed. (C) Relative expression of MYC mRNA in a panel of established human breast cell lines (Neve et al., 2006). The error bars represent means ± SEM. P-values were calculated by two-tailed Student’s t test.